Precision Value & Health President Dan Renick speaks with Ryan Black from Healthcare Analytics News, discussing the evolution of precision medicine and the importance of demonstrating value for new therapies to encourage reimbursement. (more…)
Pharmaceutical companies face many challenges: developing life-changing products that meet the needs of patients, physicians, and payers; adhering to regulatory standards; and managing health technology and payer scrutiny—all while trying to satisfy investors. (more…)
With the growth and increasing applications of mHealth come the need to regulate, and the biopharmaceutical industry and regulatory bodies such as the FDA are coming together to develop frameworks for mHealth utilization in clinical trials. (more…)
NEW ALIGNMENT OF INDUSTRY-LEADING SERVICES PROVIDES INTEGRATED SCIENCE, RESEARCH, TECHNOLOGY, ANALYTICS, AND COMMUNICATIONS TO INNOVATORS IN LIFE SCIENCES
Bethesda, MD – September 21, 2017 – Precision Medicine Group, a specialized services company supporting next generation approaches to drug development and commercialization, today announced the formation of Precision Value & Health—a focused set of complementary services working in concert to help pharmaceutical and life sciences clients establish the clinical, economic, and humanistic value of innovative therapies to payers, healthcare professionals, and patients.
In the latest edition of ClinicalOMICS, Precision for Medicine President Chad Clark elaborates on the recent acquisition of rare and orphan CRO Agility Clinical. (more…)
Tracy Walker from Managed Healthcare Executive talks with Precision for Value’s Jeremy Schafer regarding Kymriah, the first gene therapy approved for cancer treatment. (more…)
Extending Precision’s Capabilities Into One of the Fastest Growing Areas of Drug Development
Bethesda, MD and Carlsbad, CA – September 6, 2017 – Precision for Medicine, part of the Precision Medicine Group, announced today it has acquired Agility Clinical (“Agility”), the leading contract research organization (CRO) focused specifically on clinical development of rare disease and orphan therapies. The acquisition creates the first comprehensive, fully integrated orphan therapy clinical development services provider, combining the highest standards in global clinical trial execution and biometrics expertise with sophisticated biomarker and specialty lab capabilities. (more…)
In a new commentary for US News & World Report, Precision Health Economics’ senior research economist Jason Shafrin defines and elaborates on the field of precision medicine. (more…)
In a new article on PM360, Precision for Value executive vice president Bruce Leavitt provides step-by-step guidance for drug makers who find their product on one of the recently released formulary exclusion lists. (more…)
In the latest edition of Managed Healthcare Executive, Jeremy Schafer, Precision for Value senior vice president, director of payer access solutions, discusses value in oncology and explains how payers are using value frameworks in their drug management process. (more…)